Journal of Epidemiology and Global Health

Volume 8, Issue 3-4, December 2018, Pages 220 - 224

Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis from the Northern Region of India

Authors
Rakesh Yadav1, Aastha Saini1, Jureka Mankotia2, Rajiv Khaneja3, Priyanka Agarwal4, Sunil Sethi1, *
1Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2Intermediate Reference Laboratory, Dharampur, Himachal Pradesh, India
3State TB Cell, RNTCP, Sector 34, Chandigarh, India
4WHO Country Office for India, New Delhi, India
* Corresponding author. Email: sunilsethi10@hotmail.com
Corresponding Author
Sunil Sethi
Received 14 December 2017, Accepted 26 February 2018, Available Online 31 December 2018.
DOI
10.2991/j.jegh.2018.02.100How to use a DOI?
Keywords
Tuberculosis; cross resistance; mutation; MAS PCR; DNA sequencing
Abstract

Rapid detection of drug resistance in Mycobacterium tuberculosis is important for the successful treatment of tuberculosis. Fluoroquinolone and aminoglycoside resistance detection by molecular methods becomes more complex due to cross resistance among them. Thus, we aimed to determine cross-resistance and mutations in resistance genes for these drugs. A total of 336 multidrug-resistant tuberculosis (MDR-TB) cases received in Mycobacteriology laboratory were screened for phenotypic drug sensitivity testing for second-line drugs, i.e., ofloxacin, amikacin, kanamycin, and capreomycin. Molecular characterization of resistance was done by DNA sequencing of gyrA gene for fluoroquinolones (FQ), and multiplex allele-specific polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (RFLP) of rrs gene for aminoglycosides. Of 336 MDR-TB isolates, 12 were extensively drug-resistant tuberculosis and 219 were sensitive to all the drugs tested. Ofloxacin, amikacin, kanamycin, and capreomycin resistance was detected in 101 (30.1%), 23 (6.8%), 27 (8.1%), and 19 (5.6%) cases, respectively. Eight different mutations were detected in gyrA gene in ofloxacin-resistant isolates and A1401G nucleotide change in rrs gene were seen in 55.6% (15/27), 65.2% (15/23), and 68.4% (13/29) for kanamycin-, amikacin-, and capreomycin-resistant isolates, respectively. Information on second-line drug resistance-associated mutations could potentially be used for development of newer rapid diagnostic tests.

Copyright
© 2018 Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license (http://creativecommons.org/licences/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Journal of Epidemiology and Global Health
Volume-Issue
8 - 3-4
Pages
220 - 224
Publication Date
2018/12/31
ISSN (Online)
2210-6014
ISSN (Print)
2210-6006
DOI
10.2991/j.jegh.2018.02.100How to use a DOI?
Copyright
© 2018 Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license (http://creativecommons.org/licences/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Rakesh Yadav
AU  - Aastha Saini
AU  - Jureka Mankotia
AU  - Rajiv Khaneja
AU  - Priyanka Agarwal
AU  - Sunil Sethi
PY  - 2018
DA  - 2018/12/31
TI  - Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis from the Northern Region of India
JO  - Journal of Epidemiology and Global Health
SP  - 220
EP  - 224
VL  - 8
IS  - 3-4
SN  - 2210-6014
UR  - https://doi.org/10.2991/j.jegh.2018.02.100
DO  - 10.2991/j.jegh.2018.02.100
ID  - Yadav2018
ER  -